3,3-二甲基-1-(1-哌嗪基)-1-丁酮 | 253175-46-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 3,3-二甲基-1-(1-哌嗪基)-1-丁酮
• 英文名称: 3,3-Dimethyl-1-(piperazin-1-yl)butan-1-one
• 英文别名: 3,3-dimethyl-1-piperazin-1-ylbutan-1-one
• CAS: 253175-46-1
• 化学式: C₁₀H₂₀N₂O
• mdl: MFCD08444700
• 分子量: 184.282
• InChiKey: AXTVUKIOKILONV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  32.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  3,3-二甲基-1-(1-哌嗪基)-1-丁酮 在 4-二甲氨基吡啶 、 碳酸氢钠 、 三乙胺 作用下， 以 二氯甲烷 为溶剂， 生成 benzyl (2S,3R)-3-(3-((Z)-2,3-bis((benzyloxy)carbonyl)guanidino)propyl)-1-(4-(3,3-dimethylbutanoyl)piperazine-1-carbonyl)-4-oxoazetidine-2-carboxylate
  参考文献：
  名称：

  Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

  摘要：

  A series of N1-activated C4-carboxy azetidinones was prepared and tested as inhibitors of human tryptase. The key stereochemical and functional features required for potency, serine protease specificity and aqueous stability were determined. From these studies compound 2, BMS-262084, was identified as a potent and selective tryptase inhibitor which, when dosed intratracheally in ovalbumin-sensitized guinea pigs, reduced allergen-induced bronchoconstriction and inflammatory cell infiltration into the lung. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00688-1
• 作为产物：
  描述：

  3,3-二甲基丁酰氯 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 3,3-二甲基-1-(1-哌嗪基)-1-丁酮
  参考文献：
  名称：

  Synthesis and SAR of 4-carboxy-2-azetidinone mechanism-based tryptase inhibitors

  摘要：

  A series of N1-activated C4-carboxy azetidinones was prepared and tested as inhibitors of human tryptase. The key stereochemical and functional features required for potency, serine protease specificity and aqueous stability were determined. From these studies compound 2, BMS-262084, was identified as a potent and selective tryptase inhibitor which, when dosed intratracheally in ovalbumin-sensitized guinea pigs, reduced allergen-induced bronchoconstriction and inflammatory cell infiltration into the lung. (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0960-894x(02)00688-1

文献信息

• Beta lactam compounds and their use as inhibitors of tryptase
  申请人：Bristol-Myers Squibb Co.

  公开号：US06335324B1

  公开（公告）日：2002-01-01

  Compounds of the formulas: are disclosed. These compounds inhibit tryptase as well as other enzyme systems or are selective tryptase inhibitors and are useful as antiinflammatory agents particularly in the treatment of chronic asthma.

  这些化合物的结构式已被披露。这些化合物抑制色胺酸蛋白酶以及其他酶系统，或者是选择性色胺酸蛋白酶抑制剂，并且在特别是治疗慢性哮喘方面作为抗炎药物是有用的。
• [EN] 1,2,4-OXADIAZOLE SUBSTITUTED PIPERIDINE AND PIPERAZINE DERIVATIVES AS SMO ANTAGONISTS<br/>[FR] DÉRIVÉS DE PIPÉRIDINE OU PIPÉRAZINE SUBSTITUÉS PAR 1,2,4-OXADIAZOLE COMME ANTAGONISTES DE SMO
  申请人：ANGELETTI P IST RICHERCHE BIO

  公开号：WO2010013037A1

  公开（公告）日：2010-02-04

  The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts, stereoisomers or tautomers thereof which are inhibitors of the Sonic Hedgehog pathway, in particular Smo antagonists. Thus the compounds of this invention are useful for the treatment of diseases associated with abnormal hedgehog pathway activation, including cancer, for example basal cell carcinoma, medulloblastoma, prostate, pancreatic, breast, colon, bone and small cell lung cancers, and cancers of the upper GI tract.

  本发明涉及式(I)的化合物及其药学上可接受的盐、立体异构体或互变异构体，这些化合物是Sonic Hedgehog途径的抑制剂，特别是Smo拮抗剂。因此，本发明的化合物对治疗与异常Hedgehog途径激活相关的疾病有用，包括癌症，例如基底细胞癌、髓母细胞瘤、前列腺、胰腺、乳腺、结肠、骨骼和小细胞肺癌，以及上消化道的癌症。
• [EN] PYRAZOLOPYRIMIDINE COMPOUNDS AND METHODS OF USE THEREOF<br/>[FR] COMPOSÉS PYRAZOLOPYRIMIDINE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：HOFFMANN LA ROCHE

  公开号：WO2018122212A1

  公开（公告）日：2018-07-05

  Compounds of Formula (IA), or a pharmaceutically acceptable salt thereof, and methods of use as Janus kinase inhibitors are described herein.

  化合物的结构式（IA），或其药用可接受的盐，以及作为Janus激酶抑制剂的使用方法在此处描述。
• DISUBSTITUTED PYRAZOLE COMPOUNDS
  申请人：Eli Lilly and Company

  公开号：US20200392118A1

  公开（公告）日：2020-12-17

  The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.

  本发明提供了一种I式化合物或其药学上可接受的盐，并且利用I式化合物治疗代谢性疾病，如2型糖尿病、心力衰竭、糖尿病肾病和非酒精性脂肪肝炎。
• [(1,3‐Bis{2,6‐bis(diphenylmethyl)‐4‐methylphenyl}imidazole‐2‐ylidene)PdCl ₂ (NEt ₃ )]: “Throwing Away” a Different Ancillary Ligand to Enhance the Catalytic Activity at Room Temperature
  作者：Daniel Guest、Ming‐Tsz Chen、Graham J. Tizzard、Simon J. Coles、Michael Lewis Turner、Oscar Navarro

  DOI：10.1002/ejic.201400072

  日期：2014.5

  recent years has led to remarkable achievements in cross-coupling reactions. In this work, we show that a careful selection of the ancillary ligands that complete the catalyst/precatalyst can provide an extra level of performance. Low loadings of [(IPr*)PdCl2(TEA)] IPr* = 1,3-bis[2,6-bis(diphenylmethyl)-4-methylphenyl]imidazole-2-ylidene, TEA = triethylamine} catalyze the Buchwald-Hartwig amination

  近年来，在催化配体设计方面的大量努力已经在交叉偶联反应方面取得了显著成就。在这项工作中，我们表明仔细选择完成催化剂/预催化剂的辅助配体可以提供额外的性能水平。[(IPr*)PdCl2(TEA)] IPr* = 1,3-双[2,6-双(二苯基甲基)-4-甲基苯基]咪唑-2-亚基，TEA = 三乙胺}的低负载量催化 Buchwald-芳基氯化物的 Hartwig 胺化反应在室温下以优异的产率进行，不需要惰性气氛来建立或进行反应。